OTCMKTS:BMXMF

bioMérieux Stock Forecast, Price & News

$131.25

-2.00 (-1.50 %)

(As of 04/20/2021 12:00 AM ET)

Add

Compare

Today's Range

$131.25

Now: $131.25▼

$131.25

50-Day Range

$123.00

MA: $129.45▼

$137.28

52-Week Range

$120.25

Now: $131.25▼

$170.55

Volume50 shs

Average Volume187 shs

Market Capitalization$15.53 billion

P/E Ratio50.87

Dividend YieldN/A

Beta0.15

bioMÃ©rieux S.A. provides vitro diagnostic solutions systems for private and hospital laboratories, primarily for the diagnosis of infectious diseases. The company offers microbiology technology that identifies microorganism present in biological samples; and immunoassays technology based on antigen-antibody reaction, detects and measures infectious agents, such as bacteria, viruses, and parasites, as well as pathological markers. It also provides molecular biology for the detection of genetic sequences of deoxyribonucleic acid or ribonucleic acid; and companion diagnostic test, as well as services for clinical and industrial laboratories. The company was formerly known as B-D MÃ©rieux. bioMÃ©rieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMÃ©rieux S.A. is a subsidiary of Institut MÃ©rieux SA.

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Private households

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:BMXMF

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.biomerieux.com

Phone33-4-78-87-20-00

Employees12,800

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio50.87

Forward P/E Ratio28.53

P/E GrowthN/A

Sales & Book Value

Annual Sales$3.00 billion

Price / Sales5.18

Cash Flow$4.09 per share

Price / Cash Flow32.06

Book Value$21.33 per share

Price / Book6.15

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares118,361,000

Market Cap$15.53 billion

Next Earnings Date5/26/2021 (Estimated)

OptionableNot Optionable

Headlines

bioMérieux S.A. (OTCMKTS:BMXMF) Given Average Rating of "Hold" by Analysts
April 14, 2021 | americanbankingnews.com

bioMérieux (OTCMKTS:BMXMF) Shares Up 4%
April 14, 2021 | americanbankingnews.com

bioMérieux - 2020 Financial Results
March 23, 2021 | finanznachrichten.de

bioMérieux - First-Half 2020 Results
September 29, 2020 | finanznachrichten.de

French labs show how global supply bottlenecks thwart effort to ramp up testing
September 27, 2020 | finance.yahoo.com

What Makes BIOMERIEUX (BMXMF) a New Buy Stock
September 10, 2020 | finance.yahoo.com

COVID-19 Diagnostics Market Clinical Reviews by Expert and Healthcare Analysis 2020
September 5, 2020 | marketwatch.com

bioMérieux SA (BMXMF) CEO Alexandre Mérieux on Q2 2020 Results - Earnings Call Transcript
September 3, 2020 | seekingalpha.com

bioMérieux S.A. 2020 Q2 - Results - Earnings Call Presentation
September 2, 2020 | seekingalpha.com

What Makes BIOMERIEUX (BMXMF) a New Strong Buy Stock
July 27, 2020 | finance.yahoo.com

BIOFIRE® Respiratory Panel 2.1 plus with SARS-CoV-2 is CE marked
July 15, 2020 | finance.yahoo.com

bioMérieux: Description of the New Share Buyback Program Pursuant to Article 241-1 to Article 241-6 of the AMF General Regulations
June 30, 2020 | finance.yahoo.com

bioMérieux Issues a €200 Million Euro PP Bond
June 29, 2020 | finance.yahoo.com

Drugs standards group nixes plan to kick pharma's crab blood habit
May 30, 2020 | finance.yahoo.com

All You Need to Know About BIOMERIEUX (BMXMF) Rating Upgrade to Buy
May 27, 2020 | finance.yahoo.com

bioMérieux: Notice of Information Related to Preparatory Documents for the Ordinary and Extraordinary Shareholders’ Meeting of June 30, 2020
May 23, 2020 | finance.yahoo.com

CE Marking of bioMérieux Serology Tests for SARS-CoV-2 on VIDAS®
May 21, 2020 | finance.yahoo.com

Information Concerning 2019 Dividend and the bioMérieux General Shareholders’ Meeting
May 19, 2020 | finance.yahoo.com

bioMérieux Serology Tests for SARS-CoV-2 on VIDAS® Undergo Validation Preceding Imminent Launch
May 6, 2020 | finance.yahoo.com

bioMérieux S.A. (EPA:BIM) Earns A Nice Return On Capital Employed
May 4, 2020 | finance.yahoo.com

See More Headlines

MarketRank^™

Overall MarketRank^™

0.50 out of 5 stars

Medical Sector

1588th out of 2,018 stocks

Private Households Industry

294th out of 377 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for bioMérieux.

2.5 Community Rank

Outperform Votes
bioMérieux has received 105 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
bioMérieux has received 105 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
bioMérieux has received 50.00% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about bioMérieux and other stocks. Vote “Outperform” if you believe BMXMF will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BMXMF will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
bioMérieux does not currently pay a dividend.
Dividend Growth
bioMérieux does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, bioMérieux insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Earnings Growth
Earnings for bioMérieux are expected to decrease by -7.39% in the coming year, from $4.60 to $4.26 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of bioMérieux is 50.87, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.49.
Price to Earnings Ratio vs. Sector
The P/E ratio of bioMérieux is 50.87, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 44.78.
Price to Book Value per Share Ratio
bioMérieux has a P/B Ratio of 6.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$131.25

-2.00 (-1.50 %)

(As of 04/20/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive BMXMF News and Ratings via Email

Sign-up to receive the latest news and ratings for BMXMF and its competitors with MarketBeat's FREE daily newsletter.

bioMérieux (OTCMKTS:BMXMF) Frequently Asked Questions

Is bioMérieux a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for bioMérieux in the last twelve months. There are currently 3 sell ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" bioMérieux stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BMXMF, but not buy additional shares or sell existing shares.
View analyst ratings for bioMérieux or view top-rated stocks.

What stocks does MarketBeat like better than bioMérieux?

Wall Street analysts have given bioMérieux a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but bioMérieux wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is bioMérieux's next earnings date?

bioMérieux is scheduled to release its next quarterly earnings announcement on Wednesday, May 26th 2021.
View our earnings forecast for bioMérieux.

How has bioMérieux's stock price been impacted by COVID-19?

bioMérieux's stock was trading at $91.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BMXMF shares have increased by 43.4% and is now trading at $131.25.
View which stocks have been most impacted by COVID-19.

Who are bioMérieux's key executives?

bioMérieux's management team includes the following people:

Mr. Guillaume Bouhours, Exec. VP of Purchasing and Information Systems & CFO (Age 45)
Mr. Pierre Boulud, Exec. VP of Clinical Operations & COO (Age 50)
Sylvain Morgeau, Investor Relations
Ms. Esther Wick, Exec. VP of Legal, IP & Compliance
Mr. FranÃ§ois Lacoste, Exec. VP of R&D
Mr. Mark Miller, Exec. VP & Chief Medical Officer
Mr. Pierre Charbonnier, Exec. VP of Global Quality, Manufacturing & Supply Chain

Who are some of bioMérieux's key competitors?

Some companies that are related to bioMérieux include Daikin Industries,Ltd. (DKILY), Pjsc Lukoil (LUKOY), DENSO (DNZOY), Oriental Land (OLCLY), A.P. Møller - Mærsk A/S (AMKBY), Jardine Matheson (JMHLY), ITOCHU (ITOCY), HOYA (HOCPY), Sun Hung Kai Properties (SUHJY), Bank of Communications (BCMXY), The Swatch Group (SWGAY), Henkel AG & Co. KGaA (HENKY), Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München (MURGY), China Shenhua Energy (CSUAY) and SMC (SMCAY).
View all of BMXMF's competitors.

What is bioMérieux's stock symbol?

bioMérieux trades on the OTCMKTS under the ticker symbol "BMXMF."

How do I buy shares of bioMérieux?

Shares of BMXMF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is bioMérieux's stock price today?

One share of BMXMF stock can currently be purchased for approximately $131.25.

How much money does bioMérieux make?

bioMérieux has a market capitalization of $15.53 billion and generates $3.00 billion in revenue each year. The company earns $305.54 million in net income (profit) each year or $2.58 on an earnings per share basis.

How many employees does bioMérieux have?

bioMérieux employs 12,800 workers across the globe.

What is bioMérieux's official website?

The official website for bioMérieux is www.biomerieux.com.

Where are bioMérieux's headquarters?

bioMérieux is headquartered at 376 Chemin De l`Orme, Marcy l`Etoile I0, 69280.

How can I contact bioMérieux?

bioMérieux's mailing address is 376 Chemin De l`Orme, Marcy l`Etoile I0, 69280. The company can be reached via phone at 33-4-78-87-20-00 or via email at [email protected]

This page was last updated on 4/20/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here